Roth 'Encouraged' to See Bavituximab Moving Forward; Affirms Peregrine Pharma (PPHM) at 'Buy'
Tweet Send to a Friend
Roth Capital affirms Peregrine Pharma (Nasdaq: PPHM) at Buy with a price target of $5 following an earlier announcement that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
